A phase II study of gemcitabine and immunotherapy in renal cancer: preliminary results and review of the literature.
Zustovich
F
F
O.U.C. Medical Oncology, Busonera Hospital 1 floor, National Oncology Institute of Veneto (IOV - IRCCS ) Padua, Italy. fzustovich@ulss16.padova.it
Cartei
G
G
Dal Bianco
M
M
De Zorzi
L
L
Ceravolo
R
R
Zovato
S
S
Salmaso
F
F
Binato
S
S
Artioli
G
G
Cingarlini
S
S
Pastorelli
D
D
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D016898:Interferon-alpha / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D019772:Topotecan / Q000008:administration & dosage; D000093542:Gemcitabine
D016898:Interferon-alpha; D007376:Interleukin-2; D003841:Deoxycytidine; D019772:Topotecan; D000093542:Gemcitabine